探索 COVID-19 的有效治疗方法:进展与前景综述

Oritoke M. Okeowo, Nzube F. Olung, O. Ijomone, Ayotunde S. Adeagbo
{"title":"探索 COVID-19 的有效治疗方法:进展与前景综述","authors":"Oritoke M. Okeowo, Nzube F. Olung, O. Ijomone, Ayotunde S. Adeagbo","doi":"10.2174/0126667975267776231117052825","DOIUrl":null,"url":null,"abstract":"\n\nGlobal health and economy have been severely impacted by the COVID-19 pandemic that\nwas brought on by the SARS-CoV-2 coronavirus. This makes the creation of potent medications for\nthe treatment of COVID-19 disease a top goal. In clinical trials, several medications that have been\nrepurposed for the treatment of COVID-19 have shown promise. Nevertheless, there are a lot of obstacles to overcome in the creation of COVID-19 pharmacological therapy. The inability to pinpoint\nprospective treatment targets is one difficulty caused by the unclear etiology of COVID-19. Another\ndifficulty is the virus' quick evolution, which can result in the creation of drug-resistant variants.\nFurthermore, the quick start of clinical trials has been prompted by the strong demand for effective\ntherapies. A lack of reliable data on the safety and efficacy of medications can result from the early\nstart of clinical trials that have been prompted by the strong demand for effective medicines. Despite\nthese obstacles, the development of various promising pharmacological treatments for COVID-19\nhas advanced. These include immune-modulating medications, like dexamethasone and tocilizumab,\nas well as antiviral medicines, like remdesivir and favipiravir. Combination therapies using several\nmedications may also be useful in enhancing outcomes for COVID-19 patients. Despite some encouraging advancements, there are still a lot of obstacles to be addressed in the development of\npharmacological therapy for COVID-19. Further research is needed to identify the most effective\ntreatment approaches for this disease.\n","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":"14 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring Effective Therapeutic Approaches for COVID-19: A Review on\\nProgress and Prospects\",\"authors\":\"Oritoke M. Okeowo, Nzube F. Olung, O. Ijomone, Ayotunde S. Adeagbo\",\"doi\":\"10.2174/0126667975267776231117052825\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nGlobal health and economy have been severely impacted by the COVID-19 pandemic that\\nwas brought on by the SARS-CoV-2 coronavirus. This makes the creation of potent medications for\\nthe treatment of COVID-19 disease a top goal. In clinical trials, several medications that have been\\nrepurposed for the treatment of COVID-19 have shown promise. Nevertheless, there are a lot of obstacles to overcome in the creation of COVID-19 pharmacological therapy. The inability to pinpoint\\nprospective treatment targets is one difficulty caused by the unclear etiology of COVID-19. Another\\ndifficulty is the virus' quick evolution, which can result in the creation of drug-resistant variants.\\nFurthermore, the quick start of clinical trials has been prompted by the strong demand for effective\\ntherapies. A lack of reliable data on the safety and efficacy of medications can result from the early\\nstart of clinical trials that have been prompted by the strong demand for effective medicines. Despite\\nthese obstacles, the development of various promising pharmacological treatments for COVID-19\\nhas advanced. These include immune-modulating medications, like dexamethasone and tocilizumab,\\nas well as antiviral medicines, like remdesivir and favipiravir. Combination therapies using several\\nmedications may also be useful in enhancing outcomes for COVID-19 patients. Despite some encouraging advancements, there are still a lot of obstacles to be addressed in the development of\\npharmacological therapy for COVID-19. Further research is needed to identify the most effective\\ntreatment approaches for this disease.\\n\",\"PeriodicalId\":10815,\"journal\":{\"name\":\"Coronaviruses\",\"volume\":\"14 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Coronaviruses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0126667975267776231117052825\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126667975267776231117052825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

由SARS-CoV-2冠状病毒引发的COVID-19大流行对全球卫生和经济造成了严重影响。这使得开发治疗COVID-19疾病的有效药物成为首要目标。在临床试验中,几种被重新用于治疗COVID-19的药物显示出了希望。尽管如此,在新冠病毒药物治疗的创造过程中,仍有许多障碍需要克服。由于COVID-19的病因不明,无法确定未来的治疗靶点是一个困难。另一个困难是病毒的快速进化,这可能导致产生耐药变种。此外,对有效疗法的强烈需求推动了临床试验的快速启动。由于对有效药物的强烈需求,临床试验过早开始,可能导致缺乏关于药物安全性和有效性的可靠数据。尽管存在这些障碍,但针对covid -19的各种有希望的药物治疗方法的开发取得了进展。这些药物包括免疫调节药物,如地塞米松和托珠单抗,以及抗病毒药物,如瑞德西韦和法匹拉韦。使用多种药物的联合治疗也可能有助于提高COVID-19患者的预后。尽管取得了一些令人鼓舞的进展,但在COVID-19药物治疗的开发过程中仍有许多障碍需要解决。需要进一步的研究来确定这种疾病最有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring Effective Therapeutic Approaches for COVID-19: A Review on Progress and Prospects
Global health and economy have been severely impacted by the COVID-19 pandemic that was brought on by the SARS-CoV-2 coronavirus. This makes the creation of potent medications for the treatment of COVID-19 disease a top goal. In clinical trials, several medications that have been repurposed for the treatment of COVID-19 have shown promise. Nevertheless, there are a lot of obstacles to overcome in the creation of COVID-19 pharmacological therapy. The inability to pinpoint prospective treatment targets is one difficulty caused by the unclear etiology of COVID-19. Another difficulty is the virus' quick evolution, which can result in the creation of drug-resistant variants. Furthermore, the quick start of clinical trials has been prompted by the strong demand for effective therapies. A lack of reliable data on the safety and efficacy of medications can result from the early start of clinical trials that have been prompted by the strong demand for effective medicines. Despite these obstacles, the development of various promising pharmacological treatments for COVID-19 has advanced. These include immune-modulating medications, like dexamethasone and tocilizumab, as well as antiviral medicines, like remdesivir and favipiravir. Combination therapies using several medications may also be useful in enhancing outcomes for COVID-19 patients. Despite some encouraging advancements, there are still a lot of obstacles to be addressed in the development of pharmacological therapy for COVID-19. Further research is needed to identify the most effective treatment approaches for this disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信